Skip to main content

Table 1 Baseline characteristics

From: Using pharmacists to improve risk stratification and management of stage 3A chronic kidney disease: a feasibility study

 

Control (n = 23)

Pharmacist MTM (N = 24)

Age, y

70.6 (9.7)

64.0 (13.2)

Female, %

52.2 %

62.5 %

SBP, mmHg

142.3 (16.4)

145.1 (19.7)

DBP, mmHg

77.7 (11.4)

81.3 (15.1)

eGFR, ml/min/1.73 m2

53.8 (5.8)

54.1 (7.7)

Current smoker, %

4.3 %

8.3 %

Hypertension, %

95.6 %

91.7 %

Diabetes, %

34.8 %

16.7 %

Coronary artery disease, %

17.4 %

20.8 %

Dyslipidemia, %

73.9 %

66.7 %

Heart Failure, %

0 %

0 %

Taking ACEI/ARB, %

78.3 %

70.8 %

Taking statin, %

69.6 %

54.2 %

ACR categorya, %

  

<30 mg/g

47.8 %

62.5 %

30–299 mg/g

26.1 %

20.8 %

> = 300 mg/g

4.4 %

4.2 %

Missing

21.7 %

12.5 %

  1. aACR category reflects urine ACR and protein/creatinine ratio values measured during baseline or during the trial for individuals missing baseline data (n = 23). Protein/creatinine ratio values (g/g) were converted to urine albumin/creatinine ratios (mg/g) by dividing protein/creatinine ratios by 0.0017566 if female and dividing by 0.002655 if male
  2. Abbreviations: SBP systolic blood pressure, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, ACR albumin/creatinine ratio
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us